For biopharma M&A, the best returns come from small deals: analysts

Submitted by admin on April 9, 2024 - 11:14am

Source:

Fierce Pharma

News Tags:

M&A

Bristol Myers Squibb

AbbVie

Headline:

For biopharma M&A, the best returns come from small deals: analysts

snippet:

Last year closed with a flurry of big-money biopharma deals. Of the industry’s top 10 acquisitions, six came in the fourth quarter. Bristol Myers Squibb pulled off three of these buyouts in the final three months of 2023, spending a combined $23 billion, while AbbVie inked a pair of deals totaling $19 billion.

Search form

You are here

For biopharma M&A, the best returns come from small deals: analysts

For biopharma M&A, the best returns come from small deals: analysts